Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Buy

Wall Street Data Solutions Rating

Neutral

B

InMed Pharmaceuticals Inc. Common Shares (INM)

Pharmaceutical Preparations

https://www.inmedpharma.com

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

SUITE 310, 815 W. HASTINGS STREET
VANCOUVER, A1

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/01/1970

Market Cap

1,327,140

Shares Outstanding

5,260,000

Weighted SO

6,600,924

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

QNRX --.--%

ALLR --.--%

KRBP --.--%

VRAX --.--%

BDRX --.--%

ICU --.--%

VIRI --.--%

ZVSA --.--%

SONN --.--%

Beta

0.5970

Last Div

0.0000

Range

0.121-2.08

Chg

0.0048

Avg Vol

1466582

Mkt Cap

1327140

Exch

NASDAQ

Country

CA

Phone

604 669 7207

DCF Diff

N/A

DCF

0.0000

Div Yield

0.0000

P/S

0.2069

EV Multiple

0.8433

P/FV

0.1288

Div Yield %

0.0000

P/E

-0.2354

PEG

-0.0094

Payout

0.0000

Current Ratio

6.5828

Quick Ratio

5.8019

Cash Ratio

4.9715

DSO

11.8195

DIO

99.9850

Op Cycle

111.8045

DPO

33.7181

CCC

78.0865

Gross Margin

0.3204

Op Margin

-1531.5901

Pretax Margin

-0.9472

Net Margin

-0.9474

Eff Tax Rate

0.0351

ROA

-0.4549

ROE

-0.5337

ROCE

-830.3315

NI/EBT

1.0003

EBT/EBIT

0.0006

EBIT/Rev

-1531.5901

Debt Ratio

0.0802

D/E

0.0964

LT Debt/Cap

0.0613

Total Debt/Cap

0.0879

Int Coverage

-96.1517

CF/Debt

-6.2051

Equity Multi

1.2030

Rec Turnover

30.8811

Pay Turnover

10.8251

Inv Turnover

3.6505

FA Turnover

4.6780

Asset Turnover

0.4801

OCF/Share

-0.6912

FCF/Share

-0.6956

Cash/Share

0.7951

OCF/Sales

-1.0360

FCF/OCF

1.0065

CF Coverage

-6.2051

ST Coverage

-19.2284

CapEx Coverage

-154.8887

Div&CapEx Cov

-154.8887

P/BV

0.1288

P/B

0.1288

P/S

0.2069

P/E

-0.2354

P/FCF

-0.1985

P/OCF

-0.2153

P/CF

-0.2153

PEG

-0.0094

P/S

0.2069

EV Multiple

0.8433

P/FV

0.1288

DPS

0.0000

Latest Headlines (EST)

The Motley Fool Jan 07, 08:30 3 Boneheaded Investing Mistakes I Pledge Not to Make (Again) in 2024 and Beyond The Motley Fool Jan 07, 08:30 3 Boneheaded Investing Mistakes I Pledge Not to Make (Again) in 2024 and Beyond The Motley Fool Jan 07, 08:30 3 Boneheaded Investing Mistakes I Pledge Not to Make (Again) in 2024 and Beyond The Motley Fool Jan 07, 08:30 3 Boneheaded Investing Mistakes I Pledge Not to Make (Again) in 2024 and Beyond The Motley Fool Jan 07, 08:30 3 Boneheaded Investing Mistakes I Pledge Not to Make (Again) in 2024 and Beyond The Motley Fool Jan 07, 08:30 3 Boneheaded Investing Mistakes I Pledge Not to Make (Again) in 2024 and Beyond Zacks Investment Research Dec 29, 09:30 Is InMode (INMD) a Buy as Wall Street Analysts Look Optimistic? Benzinga Dec 17, 22:14 Investment Chief At $48B Global X Forecasts AI Stock Dominance In 2024: Unveils Top Investment Opportunities Benzinga Dec 17, 22:14 Investment Chief At $48B Global X Forecasts AI Stock Dominance In 2024: Unveils Top Investment Opportunities Benzinga Dec 17, 22:14 Investment Chief At $48B Global X Forecasts AI Stock Dominance In 2024: Unveils Top Investment Opportunities Benzinga Dec 17, 22:14 Investment Chief At $48B Global X Forecasts AI Stock Dominance In 2024: Unveils Top Investment Opportunities Benzinga Dec 17, 22:14 Investment Chief At $48B Global X Forecasts AI Stock Dominance In 2024: Unveils Top Investment Opportunities The Motley Fool Dec 06, 05:40 2 Small-Cap Stocks With Big Potential in 2024 The Motley Fool Dec 02, 08:10 2 Magnificent Stocks That Could Go Parabolic GlobeNewswire Inc. Nov 30, 14:34 Minim Inc. Responds to Unusual Trading GlobeNewswire Inc. Nov 30, 14:34 Minim Inc. Responds to Unusual Trading GlobeNewswire Inc. Nov 20, 12:35 Minim, Inc. Announces Receipt of Nasdaq Listing Deficiency Notice GlobeNewswire Inc. Oct 30, 09:07 INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα

Revenue Product Segmentation